Financial reports
20-F
2022 FY
Annual report (foreign)
24 Feb 23
20-F
2021 FY
Annual report (foreign)
23 Feb 22
20-F
2020 FY
Annual report (foreign)
4 Mar 21
20-F
2019 FY
Annual report (foreign)
5 Mar 20
20-F
2018 FY
Annual report (foreign)
8 Mar 19
20-F/A
2017 FY
Annual report (foreign) (amended)
16 Mar 18
20-F
2017 FY
Annual report (foreign)
7 Mar 18
20-F
2016 FY
Annual report (foreign)
3 Mar 17
20-F
2015 FY
Annual report (foreign)
4 Mar 16
20-F
2014 FY
Annual report (foreign)
11 Mar 15
Current reports
6-K
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
20 Mar 24
6-K
Current report (foreign)
27 Feb 24
6-K
Current report (foreign)
15 Feb 24
6-K
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
2 Feb 24
6-K
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
1 Feb 24
6-K
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
23 Jan 24
6-K
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
17 Jan 24
6-K
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
27 Dec 23
6-K
Current report (foreign)
20 Dec 23
6-K
Current report (foreign)
1 Dec 23
Registration and prospectus
F-3ASR
Automatic shelf registration (foreign)
4 Apr 24
S-8
Registration of securities for employees
4 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Mar 24
F-6EF
Automatic registration for ADRs (foreign)
18 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
27 Apr 23
SC TO-T/A
Third party tender offer statement (amended)
26 Apr 23
SC TO-T/A
Third party tender offer statement (amended)
10 Apr 23
S-8
Registration of securities for employees
30 Mar 23
SC TO-T
Third party tender offer statement
24 Mar 23
SC TO-C
Information about tender offer
17 Mar 23
Proxies
DFAN14A
Additional proxy materials by non-management
5 Jul 16
DFAN14A
Additional proxy materials by non-management
14 Jun 16
DEFC14A
Proxy in contested solicitation
13 Jun 16
DFAN14A
Additional proxy materials by non-management
13 Jun 16
PRRN14A
Revised preliminary proxy statement filed by non-management
9 Jun 16
DFAN14A
Additional proxy materials by non-management
8 Jun 16
DFAN14A
Additional proxy materials by non-management
8 Jun 16
PRRN14A
Revised preliminary proxy statement filed by non-management
7 Jun 16
DFAN14A
Additional proxy materials by non-management
1 Jun 16
DFAN14A
Additional proxy materials by non-management
25 May 16
Other
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
23 Feb 24
SD
Conflict minerals disclosure
30 May 23
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
24 Feb 23
SD
Conflict minerals disclosure
25 May 22
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
23 Feb 22
SD
Conflict minerals disclosure
21 May 21
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
19 May 21
SD
Conflict minerals disclosure
23 Apr 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 Mar 20
UPLOAD
Letter from SEC
27 Jan 20
Ownership
SC 13G/A
Amundi
14 Feb 24
SC 13G/A
DODGE & COX
13 Feb 24
SC 13G/A
BlackRock Inc.
6 Feb 24
SC 13G
MeiraGTx Holdings plc
6 Nov 23
11-K
Annual report of employee stock purchases
28 Jun 23
11-K
Annual report of employee stock purchases
28 Jun 23
SC 13G/A
DODGE & COX
14 Feb 23
SC 13G/A
Amundi
10 Feb 23
SC 13G/A
BlackRock Inc.
7 Feb 23
11-K
Annual report of employee stock purchases
29 Jun 22